Table 2.
Phase II trials with multikinase RET inhibitors
|
Drug
|
n
|
ORR
|
PFS
|
OS
|
| Cabozantinib[22] | 25 | 28% | 5.5 mo | 9.9 mo |
| Vandetanib[23] | 18 | 18% | 4.5 mo | 11.6 mo |
| Lenvatinib[24] | 25 | 16% | 7.3 mo | NR |
| Sorafenib[25] | 3 | 0 | NR | NR |
| Selpercatinib[26] | 105 | 64% in platinum chemotherapy pretreated | 90% in response at 6 mo | NR |
| 85% in platinum chemotherapy naïve | ||||
| Pralsetinib[27] | 106 | 61% in platinum chemotherapy pretreated | NR | NR |
| 73% in platinum chemotherapy naïve |
ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported.